Choice A rationale

Increased appetite is not a primary therapeutic effect of diphenhydramine when treating an acute allergic reaction. Diphenhydramine primarily acts as an antihistamine, blocking histamine H1 receptors to reduce symptoms like pruritus, urticaria, and angioedema. Changes in appetite are not typically a direct or expected indicator of its effectiveness in this context.

Choice B rationale

Hoarseness can be a manifestation of angioedema affecting the larynx, a serious symptom of an allergic reaction. Diphenhydramine's antihistaminic properties reduce vascular permeability and swelling by blocking histamine's effects on capillaries, thus alleviating laryngeal edema and improving voice quality. Its effectiveness in reducing swelling indicates a positive therapeutic response.

Choice C rationale

Headaches are not a typical symptom directly treated by diphenhydramine in the context of an allergic reaction. While some allergic reactions might trigger headaches, diphenhydramine's primary mechanism of action targets histamine-mediated responses, not direct analgesic effects for headache relief. Therefore, headache resolution is not a primary indicator of its effectiveness.

Choice D rationale

Diphenhydramine is known for its sedative properties due to its ability to cross the blood-brain barrier and block H1 receptors in the central nervous system. Therefore, feeling more alert would contradict the expected side effects and would not indicate the medication's effectiveness in managing allergic symptoms. Increased alertness would suggest an atypical or absent response.

Choice A rationale

Increased appetite is not a primary therapeutic effect of diphenhydramine when treating an acute allergic reaction. Diphenhydramine primarily acts as an antihistamine, blocking histamine H1 receptors to reduce symptoms like pruritus, urticaria, and angioedema. Changes in appetite are not typically a direct or expected indicator of its effectiveness in this context.

Choice B rationale

Hoarseness can be a manifestation of angioedema affecting the larynx, a serious symptom of an allergic reaction. Diphenhydramine's antihistaminic properties reduce vascular permeability and swelling by blocking histamine's effects on capillaries, thus alleviating laryngeal edema and improving voice quality. Its effectiveness in reducing swelling indicates a positive therapeutic response.

Choice C rationale

Headaches are not a typical symptom directly treated by diphenhydramine in the context of an allergic reaction. While some allergic reactions might trigger headaches, diphenhydramine's primary mechanism of action targets histamine-mediated responses, not direct analgesic effects for headache relief. Therefore, headache resolution is not a primary indicator of its effectiveness.

Choice D rationale

Diphenhydramine is known for its sedative properties due to its ability to cross the blood-brain barrier and block H1 receptors in the central nervous system. Therefore, feeling more alert would contradict the expected side effects and would not indicate the medication's effectiveness in managing allergic symptoms. Increased alertness would suggest an atypical or absent response.

Choice A rationale

Docusate sodium is a stool softener that works by increasing water and fat absorption into the stool, making it softer and easier to pass. There is no known significant pharmacokinetic or pharmacodynamic interaction between docusate sodium and haloperidol that would necessitate avoiding its use.

Choice B rationale

Bupropion is an antidepressant that acts as a norepinephrine-dopamine reuptake inhibitor. Combining bupropion with haloperidol, a dopamine receptor antagonist, can be problematic. Bupropion lowers the seizure threshold and can exacerbate dopamine-blocking effects, potentially increasing the risk of adverse neurological events or reducing haloperidol's efficacy.

Choice C rationale

Diphenhydramine is an anticholinergic medication that can exacerbate the anticholinergic side effects of haloperidol, such as dry mouth, constipation, blurred vision, and urinary retention. This combination increases the risk of anticholinergic toxicity, which can manifest as confusion, delirium, and increased intraocular pressure.

Choice D rationale

Glucosamine is a naturally occurring amino sugar that supports cartilage health and is often used for osteoarthritis. There is no documented significant drug interaction between glucosamine and haloperidol. Their mechanisms of action are entirely different, and co-administration is generally considered safe without adverse interactions.

Choice A rationale

Varenicline is a nicotinic receptor partial agonist used for smoking cessation. It acts by reducing the craving and withdrawal symptoms associated with nicotine dependence. It has no primary role in managing the acute neurological and physiological symptoms characteristic of alcohol withdrawal, which involve GABAergic and glutamatergic dysregulation.

Choice B rationale

Clonidine is an alpha-2 adrenergic agonist primarily used to treat hypertension. In alcohol withdrawal, it can help alleviate some autonomic symptoms like tachycardia and hypertension by reducing sympathetic nervous system overactivity. However, it does not address the core neurological hyperexcitability and seizure risk inherent in severe withdrawal.

Choice C rationale

Methadone is a long-acting opioid agonist used for opioid dependence treatment and pain management. It works by binding to opioid receptors, alleviating withdrawal symptoms and blocking euphoric effects of other opioids. It has no direct therapeutic application for the neurochemical imbalances and acute physical symptoms of alcohol withdrawal.

Choice D rationale

Diazepam is a long-acting benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. In alcohol withdrawal, the central nervous system is hyperexcitable due to chronic alcohol-induced GABAergic downregulation. Diazepam's GABAergic potentiation effectively reduces neuronal excitability, preventing seizures and delirium.

Choice A rationale

Expelling the air bubble from a prefilled enoxaparin syringe is not recommended. The manufacturer specifically includes a small air bubble which acts as an air lock. This air lock ensures that the entire dose is delivered and seals the medication in the tissue, preventing leakage back along the needle track and reducing bruising.

Choice B rationale

Gently massaging the injection site after enoxaparin administration is contraindicated. Massaging can disperse the medication too rapidly, potentially increasing localized bleeding, bruising, and hematoma formation at the injection site. This can also alter the absorption rate of the drug, potentially affecting its therapeutic anticoagulant effect.

Choice C rationale

Aspirating prior to injecting subcutaneous enoxaparin is not recommended. Subcutaneous injections are administered into the fatty tissue layer, which lacks major blood vessels. Aspiration is typically performed for intramuscular injections to avoid injecting directly into a vessel; for enoxaparin, aspiration increases tissue trauma and bruising risk without benefit.

Choice D rationale

Enoxaparin is optimally absorbed when injected into abdominal subcutaneous tissue, specifically into the fat pads lateral to the umbilicus. This area provides consistent absorption and is generally less sensitive, minimizing patient discomfort. Alternative sites include the anterolateral or posterolateral thigh, but the abdomen is preferred for its predictability.

Choice A rationale

Anorexia, a significant decrease in appetite leading to reduced food intake, is not a typical physiological manifestation of diazepam withdrawal. Withdrawal primarily impacts the central nervous system, leading to heightened neuronal excitability rather than appetite suppression as a primary or common symptom.

Choice B rationale

Hypotension, or abnormally low blood pressure, is generally not a direct or common physiological consequence of diazepam withdrawal. Withdrawal from benzodiazepines typically leads to sympathetic nervous system overactivity, which tends to cause hypertension and tachycardia rather than a decrease in blood pressure.

Choice C rationale

Tremors are a classic and significant manifestation of benzodiazepine withdrawal, including diazepam. This occurs due to central nervous system hyperexcitability resulting from the abrupt removal of the GABAergic inhibitory effects of diazepam, leading to neuronal overstimulation and motor instability. Normal range for tremors is none.

Choice D rationale

Drowsiness, a state of reduced alertness and increased desire to sleep, is a common side effect of diazepam use due to its central nervous system depressant effects. Conversely, withdrawal from diazepam typically leads to increased arousal, anxiety, and insomnia, rather than drowsiness.

Choice A rationale

Hypertension, or elevated blood pressure, is not a common adverse effect of dimenhydrinate. Dimenhydrinate is an antihistamine with anticholinergic properties; while some anticholinergics can cause tachycardia, they typically do not lead to significant hypertension. Blood pressure should be within normal limits, e.g., 120/80 mmHg.

Choice B rationale

Polyuria, the excessive production of urine, is not a recognized adverse effect of dimenhydrinate. Anticholinergic medications like dimenhydrinate can sometimes cause urinary retention due to relaxation of the detrusor muscle, rather than increased urine output. Normal urine output is approximately 0.5-1 mL/kg/hour.

Choice C rationale

Drowsiness is a very common and expected adverse effect of dimenhydrinate. As an H1 receptor antagonist, it readily crosses the blood-brain barrier and exerts central nervous system depression, leading to sedation and somnolence. This effect is often utilized for its antiemetic properties.

Choice D rationale

Dependent edema, the accumulation of fluid in dependent body parts, is not an adverse effect associated with dimenhydrinate. This symptom is typically linked to cardiovascular issues like heart failure or venous insufficiency, not to the pharmacological actions of antihistamines.

Choice A rationale

Hypoglycemia, or low blood glucose, is not a common or direct interaction effect between spironolactone and lisinopril. Spironolactone is a potassium-sparing diuretic, and lisinopril is an ACE inhibitor; neither medication is directly involved in glucose regulation pathways to cause hypoglycemia. Normal fasting blood glucose is 70-99 mg/dL.

Choice B rationale

Hyperkalemia, an elevated potassium level, is a significant risk when spironolactone and lisinopril are co-administered. Spironolactone is a potassium-sparing diuretic, and lisinopril, an ACE inhibitor, also reduces aldosterone secretion, both mechanisms lead to decreased potassium excretion and increased serum potassium. Normal potassium is 3.5-5.0 mEq/L.

Choice C rationale

Hyperglycemia, or elevated blood glucose, is not a typical adverse effect of either spironolactone or lisinopril, nor is it a known interaction effect between the two. These medications do not directly impact insulin sensitivity or glucose production pathways in a manner that would lead to hyperglycemia. Normal fasting blood glucose is 70-99 mg/dL.

Choice D rationale

Hypokalemia, or low potassium levels, is highly unlikely with the co-administration of spironolactone and lisinopril. Both medications tend to increase or conserve potassium. Spironolactone directly spares potassium, and lisinopril indirectly increases potassium by inhibiting aldosterone, thus preventing potassium excretion. Normal potassium is 3.5-5.0 mEq/L.

Choice A rationale

Increased blood pressure is not an expected outcome when initiating propylthiouracil therapy for Graves' disease. Graves' disease typically causes hyperthyroidism, which elevates metabolic rate and can increase blood pressure. Propylthiouracil aims to decrease thyroid hormone synthesis, which would lead to a reduction in blood pressure toward normal. Normal blood pressure is 120/80 mmHg.

Choice B rationale

A decreased WBC count, specifically agranulocytosis, is a serious and potential adverse effect of propylthiouracil, not an expected therapeutic outcome for Graves' disease. While nurses monitor for this, the therapeutic goal is to reduce thyroid hormone levels, not to suppress the immune system. Normal WBC count is 4,500-11,000 cells/mm³.

Choice C rationale

An increased Hct is not an expected outcome of propylthiouracil therapy. Hyperthyroidism in Graves' disease can sometimes lead to a slight decrease in red blood cell parameters due to increased metabolic turnover. Propylthiouracil aims to normalize thyroid function, which might indirectly normalize Hct, but not necessarily cause a significant increase. Normal Hct is 37-52%.

Choice D rationale

A decreased heart rate is an expected and desirable outcome of propylthiouracil therapy for Graves' disease. Hyperthyroidism characteristically causes tachycardia due to increased adrenergic stimulation. Propylthiouracil reduces thyroid hormone synthesis, thereby alleviating the hypermetabolic state and lowering the elevated heart rate toward normal ranges. Normal heart rate is 60-100 beats/min.

Choice A rationale

Fluid retention is not a common or primary adverse effect associated with filgrastim. Filgrastim stimulates granulocyte production and is generally well-tolerated with specific side effect profiles that do not typically include significant fluid accumulation or edema. Other medications or conditions are more commonly associated with fluid retention.

Choice B rationale

Hypertension, or elevated blood pressure, is not a frequently reported or significant adverse effect of filgrastim. While any medication can potentially affect blood pressure, filgrastim's primary mechanism of action (stimulation of neutrophil production) does not directly or commonly lead to sustained increases in blood pressure.

Choice C rationale

Bone pain is a very common and well-documented adverse effect of filgrastim. This pain is believed to result from the rapid proliferation and expansion of hematopoietic cells within the bone marrow, which is stimulated by filgrastim. The pain is typically mild to moderate and is managed with analgesics.

Choice D rationale

Hypokalemia, or low serum potassium, is not a typical adverse effect of filgrastim. Filgrastim does not directly influence potassium balance or renal function in a way that would lead to a decrease in serum potassium levels. Electrolyte imbalances are not commonly associated with its use.